CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Sildenafil citrate

Last Updated: September 20, 2006
Result type: Reports
Project Number: SR0076-000
Product Line: Reimbursement Review

Generic Name: Sildenafil citrate

Brand Name: Revatio

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Pulmonary arterial hypertension (WHO class II and III)

Indications: Pulmonary arterial hypertension (WHO class II and III)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 14, 2007

Recommendation Type: List in a similar manner